Compare Moderna, Inc. (MRNA) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.07. Which is the better fit depends on your goals.
| MRNA | VIG | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | — |
52-Week High | $174.38 | $246.61 |
52-Week Low | $22.36 | $210.70 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
VIG trades at $240.11, down 0.79% with bearish technical signals from moving averages. The ETF maintains its dividend growth strategy, with a scheduled $1.00 dividend payment in June 2026. Recent news highlights institutional accumulation and comparisons with peer dividend ETFs, emphasizing VIG's defensive tech exposure and lower yield relative to competitors like SCHD.
Outlook remains cautious near-term due to technical pressure, but long-term dividend growth appeal persists for income-focused investors. Risks include interest rate sensitivity and yield competition, while institutional buying signals underlying confidence in the strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
